Mercaptor Discoveries

What Mercaptor Discoveries does

Mercaptor Discoveries, operating as Enabled Therapeutics, Inc., is a privately-held pre-clinical biotechnology company headquartered in Novato, California, founded in 2016 (formerly focused on epilepsy and traumatic brain injury). The company develops brain-penetrant therapeutics for acute and progressive central nervous system conditions, targeting an indication portfolio that includes Alzheimer's disease, Parkinson's, Huntington's, traumatic brain injury, epilepsy, and brain inflammation in long COVID. Its core asset is the proprietary CAPTON® Technology Platform, a sulfur-biochemistry-based prodrug system that engineers small molecules (Captons) to remain pharmacologically inert in healthy tissue, traverse the blood-brain barrier via thiol-for-sulfonate substitution, and selectively re-activate at sites of neuropathology where elevated redox-active transition metals and reactive oxygen species are present. The mechanism is described as rescuing cells from ferroptosis while sparing healthy tissue, with the lead candidate CPT-021 receiving FDA regulatory alignment in March 2025 as a first-of-its-kind targeted therapy for Alzheimer's disease.

The business model is that of a pre-clinical platform biotech: there are no marketed products, no commercial revenue, no disclosed pricing, and no distribution channels. Value creation is expected through eventual licensing, partnership, or acquisition of clinical-stage assets derived from the CAPTON platform. The company's customers in a clinical sense will ultimately be neurology patients (Alzheimer's, TBI, epilepsy, etc.), but at the current stage the company's commercial counterparts are likely to be pharmaceutical partners and capital providers. Recent strategic activity has focused on regulatory advancement (FDA alignment for CPT-021), leadership reinforcement (board appointment of Jivan Achreja in April 2025), and corporate repositioning (rebrand from Mercaptor to Enabled Therapeutics) to reflect a broader precision-neurology mandate.

Go-to-market activity is limited to top-of-funnel awareness: PR distribution via PRWeb/Einpresswire, podcast appearances, and the company website's news section. No institutional investors, parent entities, or partnership agreements are disclosed. With 11–50 employees and no public funding rounds, the company appears to be operating lean, advancing a single most-advanced candidate (CPT-021) while preserving optionality across additional CNS indications enabled by the CAPTON chemistry.

Name

Mercaptor Discoveries

Legal name

Enabled Therapeutics, Inc.

Website

https://mercaptor.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Enabled Therapeutics (formerly Mercaptor Discoveries) is a pre-clinical biotech developing brain-penetrant prodrugs (Captons) using its proprietary CAPTON® sulfur-biochemistry platform to treat CNS conditions, with lead candidate CPT-021 having gained FDA alignment for Alzheimer's disease.

Ownership category

akta.pro rank

Product category

CNS Therapeutics / Neurology Drug Development

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• CNS therapeutics
• Prodrug platform
• Blood-brain barrier
• Neurology drug development
• Brain-penetrant small molecules

Headquarters

HQ city

Novato

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations

Marketing channels3 records

Core offering

Enabled Therapeutics (formerly Mercaptor Discoveries) develops a proprietary CAPTON® Technology Platform that engineers a new class of small-molecule prodrugs called "Captons" for treating acute and progressive central nervous system conditions. Captons remain pharmacologically inactive until encountering elevated redox-active transition metal ions and reactive oxygen species at brain injury sites, enabling targeted therapy for Alzheimer's disease, traumatic brain injury, epilepsy, and other neurodegenerative conditions while sparing healthy tissue.

Product overview

Mercaptor Discoveries (now Enabled Therapeutics) operates as a platform company with a proprietary Capton® Technology Platform for developing a new class of brain-penetrant prodrugs called Captons. The platform enables the development of targeted CNS therapeutics that remain inactive until activated at injury sites, addressing acute and progressive neurological conditions. Key pipeline candidates include CPT-021 for Alzheimer's disease. The company focuses on countering neuroinflammation and excitotoxicity through selective activation at sites of pathology.

Differentiator

Problem solved

Functional benefit

Brands

• CAPTON Technology: Proprietary platform technology for developing a new class of prodrugs called Captons to address acute and progressive conditions of the central nervous system. Captons are formulated from bioactive molecules engineered to efficiently reach the brain while remaining inactive in the absence of neuropathology.

Products and services

• CAPTON® Technology Platform A proprietary platform technology for engineering a new class of prodrugs called Captons — small-molecule drugs relying on sulfonic acid functional groups that are pharmacokinetically enabled and pharmacodynamically disabled via thiol substitution to enhance blood-brain barrier traversal. The platform enables development of brain-penetrant CNS therapeutics with selective activation at injury sites.
• CPT-021 CPT-021 is the lead therapeutic candidate developed using the CAPTON platform — a first-of-its-kind targeted therapy for Alzheimer's disease that received FDA alignment on its regulatory pathway. The candidate is designed to selectively activate at disease sites in the brain, addressing neuroinflammation and ferroptosis.

Quantifiable outcome

• FDA alignment achieved for CPT-021 - first-of-its-kind targeted therapy for Alzheimer's

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Cortexyme: Pre-clinical/clinical-stage CNS biotech targeting neurodegeneration (Alzheimer's) with a precision-mechanism approach. Comparable in stage, therapeutic focus, and small-team biotech profile.
• Sage Therapeutics: CNS-focused biotech developing therapeutics for neurological conditions including epilepsy and depression. Comparable as a CNS specialty company with platform-driven pipeline.
• Neumora Therapeutics: Precision neuroscience company developing brain-targeted therapeutics for neuropsychiatric and neurodegenerative disorders. Comparable as a platform biotech focused on CNS-targeted drug delivery.
• Voyager Therapeutics: Clinical-stage biotech developing gene therapies and other therapeutics for CNS diseases including Alzheimer's, Parkinson's, and Huntington's. Comparable in CNS focus and pipeline breadth.
• Denali Therapeutics: Clinical-stage biotech focused on BBB-penetrant therapeutics for neurodegenerative diseases. Directly comparable as a platform company engineering brain-targeted small molecules and biologics for Alzheimer's, Parkinson's, and ALS.
• Ionis Pharmaceuticals: Antisense-technology company with a significant CNS pipeline across Alzheimer's, ALS, and Huntington's disease. Comparable as a platform biotech with multiple CNS programs targeting neurological indications.

Emerging players

• Sangamo Therapeutics: Genomic medicine company with neurology programs including Alzheimer's. Comparable as a platform biotech pursuing multiple CNS indications with a novel delivery technology.

Broad incumbents

• Biogen: Large CNS-focused biopharmaceutical company with established Alzheimer's franchise (Aduhelm, Leqembi partnership). Sets the competitive benchmark for CNS drug development and commercialization.
• Eisai: Global pharmaceutical company with deep CNS and Alzheimer's portfolio (Leqembi co-development with Biogen). Represents the commercial incumbent against whose benchmarks Enabled Therapeutics' CPT-021 must compete.
• Eli Lilly: Major pharmaceutical company with a substantial Alzheimer's pipeline (donanemab). Defines the standard for clinical and commercial success in the Alzheimer's space Enabled Therapeutics is targeting.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/mercaptor1
• Facebookfacebook.com/MercaptorDiscoveries

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mercaptor Discoveries